Ikaros and leukaemia.

Area of Science:

• Genetics
• Molecular Biology
• Hematology

Background:

• The IKZF1 gene encodes IKAROS, a transcription factor vital for hematopoietic and lymphoid development.
• IKZF1 alterations, including deletions (ΔIKZF1), are implicated in various human malignancies.
• ΔIKZF1 is a significant genetic abnormality in pediatric B-cell precursor acute lymphoblastic leukemia (BCP ALL).

Purpose of the Study:

• To review current knowledge on IKZF1 abnormalities in human diseases.
• To emphasize the role and clinical significance of ΔIKZF1 in BCP ALL.
• To discuss how other genetic changes may influence the prognostic impact of ΔIKZF1.

Main Methods:

• Literature review of studies on IKZF1 gene.
• Analysis of genetic alterations in human malignancies, particularly BCP ALL.
• Examination of the association between ΔIKZF1 and clinical outcomes, including relapse risk and minimal residual disease.

Main Results:

• Constitutional and acquired genetic changes in IKZF1 are associated with human diseases.
• ΔIKZF1 is found in 15% of pediatric BCP ALL cases.
• The presence of ΔIKZF1 correlates with increased relapse risk and poorer outcomes in BCP ALL, potentially as an independent risk factor.

Conclusions:

• IKZF1 abnormalities, especially ΔIKZF1, have critical implications for BCP ALL prognosis.
• Cooperative genetic alterations can modify the prognostic value of ΔIKZF1.
• Further research into IKZF1's role is essential for developing targeted therapies and improving treatment strategies for BCP ALL.